Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 4, 2014JAMA

Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma

View Full Paper
Ask AI
Bookmark
Share

Authors

F. Stephen Hodi
F. Stephen HodiUniversité Paris-SudDMDavid F. McDermottBoston CollegeURUma N. M. RaoHenry M. Jackson Foundation

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hodi et al. (2014) studied this question.

synapsesocial.com/papers/6a82a0ded38da709b013352fhttps://doi.org/10.1001/jama.2014.13943
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor.1992 · 3,791 citations
  2. 2Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma2014 · 217 citations
  3. 3Nivolumab plus Ipilimumab in Advanced Melanoma2013 · 4,263 citations
  4. 4Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer2012 · 12,860 citations
  5. 5Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF2009 · 246 citations